Axsome Therapeutics, Inc.
AXSM
Positions held
Your positionsAXSM isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- Axsome Therapeutics is positioned in a growing biotechnology sector, focusing on innovative treatments that address significant unmet medical needs.
- Revenue increased by 14% compared to the prior quarter, reaching $218 million.
- Gross margin improved to 93.8%, up from 92.3% in the previous quarter.
- The company has a high debt-to-equity ratio of 269.727, indicating potential financial instability.
- Net income for 2025 is projected to be -$183.174 million, reflecting ongoing losses.
- The overall score indicates a 'Strong Sell' signal with a score of -16.00, suggesting bearish market sentiment.
Fundamentals
| Market cap | $8.91B | Enterprise value | $8.81B | Trailing P/E | — | Forward P/E | 36.17 |
| PEG | — | Price / book | 106.77 | Beta | 0.85 | Dividend yield | 0.00% |
| Revenue growth | 45.5% | Earnings growth | — | Gross margin | 93.2% | Operating margin | -23.4% |
| Profit margin | -24.7% | ROE | -2.5% | ROA | -16.3% | Debt / equity | 2.70 |
| Current ratio | 1.43 | Free cash flow | -$4.58M | Analyst recommendation | strong_buy | Mean target | $284.54 |
| 52w high | $260.19 | 52w low | $119.20 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | |
|---|---|---|---|---|---|
| Revenue | $218M | $191M | $196M | $171M | $150M |
| Op margin | -23.4% | -32.8% | -18.4% | -19.3% | -29.9% |
| Net income | -$51.3M | -$64.5M | -$28.6M | -$47.2M | -$48.0M |
| Gross margin | 93.8% | 92.3% | 93.7% | 93.0% | 91.0% |
| Gross profit | $205M | $176M | $184M | $159M | $137M |
| Operating income | -$51.1M | -$62.8M | -$36.0M | -$32.9M | -$44.8M |
- Revenue +14% vs prior quarter ($218M vs $191M).
- Gross margin 93.8% (was 92.3% prior quarter).
- Operating margin expanded to -23.4%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $638M | $386M | $271M | $50.0M | — |
| Op margin | -26.5% | -65.5% | -67.6% | -352.7% | — |
| Net income | -$183M | -$287M | -$239M | -$187M | — |
| Gross margin | 92.6% | 91.4% | 90.4% | 89.6% | — |
| Gross profit | $591M | $352M | $245M | $44.8M | — |
| Operating income | -$169M | -$252M | -$183M | -$177M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-08 · RBC Trims Price Target on Axsome Therapeutics to $295 From $297, Keeps Outperform Rating
2026-10-08 · Axsome Therapeutics vs. Moderna: Which Biotech Stock Is a Better Buy in 2026?
2026-10-07 · Axsome Therapeutics to Report Third Quarter 2026 Financial Results on November 2
2026-10-05 · Why Baird Sees Growth Potential in Axsome Therapeutics, Inc. (AXSM)
2026-10-01 · Axsome Therapeutics vs. Vertex Pharmaceuticals: Which Biotech Stock Is a Better Buy in 2026?
2026-09-30 · Jefferies Highlights Three Biotech Stocks With Blockbuster Potential
2026-09-29 · Deutsche Bank Lowers Price Target on Axsome Therapeutics to $267 From $280, Keeps Buy Rating
2026-09-23 · Truist Raises Price Target on Axsome Therapeutics to $285 From $200, Keeps Buy Rating
2026-09-19 · Axsome Sees AUVELITY Prescriptions Accelerate as Alzheimer’s Launch Gains Traction
2026-09-19 · Axsome Therapeutics (AXSM) Stock Looks Undervalued As Its 5 Year 7x Run Continues
2026-09-19 · Is Axsome Therapeutics’ (AXSM) New CNS Data Enough To Reinforce Its Neuropsychiatric Portfolio Story?
Price (daily)
Full chart · RSI · MACD · patterns